FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.21  |  FHIR Version n/a  User: [n/a]

39970511000001103: Ryaltris 25micrograms/dose / 600micrograms/dose nasal spray (Glenmark Pharmaceuticals Europe Ltd) (product)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 01-Sep 2021. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module
2002251000001112 Ryaltris 25micrograms/dose / 600micrograms/dose nasal spray (Glenmark Pharmaceuticals Europe Ltd) en Synonym Active Entire term case sensitive SNOMED CT United Kingdom drug extension module
2002261000001110 Ryaltris 25micrograms/dose / 600micrograms/dose nasal spray (Glenmark Pharmaceuticals Europe Ltd) (product) en Fully specified name Active Entire term case sensitive SNOMED CT United Kingdom drug extension module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Ryaltris 25micrograms/dose / 600micrograms/dose nasal spray (Glenmark Pharmaceuticals Europe Ltd) Has excipient Excipient not declared true Inferred relationship Existential restriction modifier
Ryaltris 25micrograms/dose / 600micrograms/dose nasal spray (Glenmark Pharmaceuticals Europe Ltd) Is a Mometasone 25micrograms/dose / Olopatadine 600micrograms/dose nasal spray true Inferred relationship Existential restriction modifier
Ryaltris 25micrograms/dose / 600micrograms/dose nasal spray (Glenmark Pharmaceuticals Europe Ltd) Has excipient Polysorbate false Inferred relationship Existential restriction modifier
Ryaltris 25micrograms/dose / 600micrograms/dose nasal spray (Glenmark Pharmaceuticals Europe Ltd) Has excipient Edetate disodium false Inferred relationship Existential restriction modifier
Ryaltris 25micrograms/dose / 600micrograms/dose nasal spray (Glenmark Pharmaceuticals Europe Ltd) Has NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction indicator NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction none true Inferred relationship Existential restriction modifier
Ryaltris 25micrograms/dose / 600micrograms/dose nasal spray (Glenmark Pharmaceuticals Europe Ltd) Is a Actual medicinal product true Inferred relationship Existential restriction modifier
Ryaltris 25micrograms/dose / 600micrograms/dose nasal spray (Glenmark Pharmaceuticals Europe Ltd) Has excipient Benzalkonium chloride false Inferred relationship Existential restriction modifier
Ryaltris 25micrograms/dose / 600micrograms/dose nasal spray (Glenmark Pharmaceuticals Europe Ltd) Is a Ryaltris true Inferred relationship Existential restriction modifier
Ryaltris 25micrograms/dose / 600micrograms/dose nasal spray (Glenmark Pharmaceuticals Europe Ltd) Has NHS dm+d (dictionary of medicines and devices) basis of strength substance Olopatadine true Inferred relationship Existential restriction modifier
Ryaltris 25micrograms/dose / 600micrograms/dose nasal spray (Glenmark Pharmaceuticals Europe Ltd) VMP prescribing status (attribute) VMP valid as a prescribable product true Inferred relationship Existential restriction modifier
Ryaltris 25micrograms/dose / 600micrograms/dose nasal spray (Glenmark Pharmaceuticals Europe Ltd) Has specific active ingredient Olopatadine hydrochloride true Inferred relationship Existential restriction modifier
Ryaltris 25micrograms/dose / 600micrograms/dose nasal spray (Glenmark Pharmaceuticals Europe Ltd) Has NHS dm+d (dictionary of medicines and devices) controlled drug category Controlled drug category No Controlled Drug Status true Inferred relationship Existential restriction modifier
Ryaltris 25micrograms/dose / 600micrograms/dose nasal spray (Glenmark Pharmaceuticals Europe Ltd) VMP non-availability indicator Available true Inferred relationship Existential restriction modifier
Ryaltris 25micrograms/dose / 600micrograms/dose nasal spray (Glenmark Pharmaceuticals Europe Ltd) Has specific active ingredient Mometasone furoate true Inferred relationship Existential restriction modifier
Ryaltris 25micrograms/dose / 600micrograms/dose nasal spray (Glenmark Pharmaceuticals Europe Ltd) Has dispensed dose form Spray dose form true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Ryaltris 25micrograms/dose / 600micrograms/dose nasal spray (Glenmark Pharmaceuticals Europe Ltd) 240 dose Has AMP True Ryaltris 25micrograms/dose / 600micrograms/dose nasal spray (Glenmark Pharmaceuticals Europe Ltd) Inferred relationship Existential restriction modifier

This concept is not in any reference sets

Back to Start